ABSTRACTS OF DECISIONS
DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS
Application : No. 716793 in the name of Euro-Celtique S. A.
Title : Opioid Formulations Having Extended Controlled Release
Action : Opposition to the grant of a patent by Grunenthal GmbH
Decision : Issued .
Abstract
The opposed invention relates to an opioid-containing solid controlled-release oral dosage form providing an extended duration of therapeutic effect of about 24 hours after administration. The opponent pursued the grounds of novelty, inventive step and manner of manufacture at hearing.
Submissions were made that certain features of the present invention were a mechanical equivalent of the prior art, and that certain parameters were an inherent feature of prior art formulations. The evidence did not support such submissions, and the claims are novel. Furthermore, the evidence did not establish that a skilled person would have been directly led to the invention in view of the prior art, and the claims meet the threshold test for inventiveness.
As the opposition has been unsuccessful on all grounds, costs are awarded against the opponent.
PATENTS ACT 1990
DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS
Re: Patent Application No. 716793 in the name of Euro-Celtique S. A., and an opposition under section 59 to the grant of a patent by Grunenthal GmbH.
BACKGROUND
- Patent application number 716793 in the name of Euro-Celtique S. A. (“the applicant”), was filed on 6 February 1998. The application was advertised accepted on 9 March 2000, and a notice of opposition was filed by Grunenthal GmbH (“the opponent”) on 9 June 2000. A statement of grounds and particulars was filed on 8 September 2000. Evidence in support was completed on 25 February 2002, evidence in answer on 18 March 2004, and evidence in reply on 22 June 2005.
- The applicant filed further evidence on 10 November 2005. Evidence in response to the further evidence was completed on 20 March 2006.
- The opposition was heard in Sydney on 30 August 2006. The applicant was represented by Mr Phillip Kerr, Solicitor, assisted by Ms Claudia Wallman and Ms Carolyn Morely of Allens Arthur Robinson, Sydney. The opponent was represented by Ms Katrina Howard of Counsel, instructed by Dr Jacinta Flattery-O'Brien of Shelston IP, Sydney. In addition to providing written submissions at hearing, both parties provided further submissions following the hearing.
GROUNDS OF OPPOSITION
- The grounds of opposition were manner of manufacture, novelty, inventive step and section 40, but only novelty, inventive step and manner of manufacture were the subject of submissions at hearing.
THE EVIDENCE
- Evidence in support consisted of declarations by:
·Stephan A. Schug, Department of Pharmacology, University of Western Australia, dated 19 February 2002 and comprising Exhibits SAS1 to SAS9.
·James Steven Rowe, Technical Consultancy Services Pty. Ltd., dated 6 February 2002 and comprising Exhibits JSR1 to JSR21.
·Denis Eng Tuffery, Shelston IP Sydney, dated 8 February 2002. This declaration merely confirmed the publication dates of a number of patents referred to in Dr Rowe’s evidence.
- Evidence in answer consisted…
Keep reading for free
Create a free CaseChat account to read Euro-Celtique S.A. v Grunenthal GmbH and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2006] APO 38
- Decision Date
CaseChat Overview and Summary
The primary legal issues before the court were whether the claimed invention was novel and possessed an inventive step over the prior art, and whether the claims defined a manner of manufacture. The opponent argued that certain features of the invention were mechanical equivalents of prior art and that the in vivo characteristics were inherent in the prior art formulations. They also contended that the claims did not define a manner of manufacture as they were based on known formulations.
The court found that the claims were novel as the prior art did not disclose a dosage form providing a therapeutic effect for about 24 hours. It concluded that while the prior art formulations had similar in vitro dissolution properties, there was no clear and unmistakable direction to the claimed invention. Regarding the inventive step, the court held that the evidence did not establish that a skilled person would have been directly led to the invention, considering the uncertainties and risks associated with increasing the drug loading to achieve the desired duration of therapeutic effect. The court also determined that the claims met the threshold for inventiveness and defined a manner of manufacture.
As the opposition was unsuccessful on all grounds, the court awarded costs against the opponent. Grunenthal GmbH had 21 days to appeal the decision, after which the application would be sealed unless an appeal was filed.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi